The quest for non-invasive treatments for drug-resistant depression and other neurological conditions just got a significant boost. Paris-based SonoMind, a medical device company specializing in low-intensity focused ultrasound, has announced a $23.5M Series A funding round.
SonoMind, led by CEO Jeremy Bercoff, is developing a portable device that delivers precision transcranial ultrasound stimulation, capable of penetrating deep brain structures accurately and non-invasively. This medical device, which uses a custom-designed acoustic lens for each patient, builds on 25 years of research from the Institut Physique pour la M茅decine in France.
